BioXcel Therapeutics (BTAI)

The company’s lead commercial product is IGALMI, a sublingual film formulation of dexmedetomidine. The US Food and Drug Administration approves IGALMI for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The product is designed to dissolve under the tongue and provides a non-invasive option in settings where rapid calming is needed without an injection.

BioXcel’s pipeline includes BXCL501, the development name behind IGALMI, which the company studies in additional agitation-related and neuropsychiatric settings. It also develops BXCL701, an oral small-molecule candidate in immuno-oncology. BXCL701 is intended to stimulate immune activity in the tumor microenvironment and is investigated in cancer indications where new combinations or immune-based approaches may improve outcomes.

As a listed biotechnology stock, BTAI gives investors exposure to a company transitioning between clinical development and commercial execution. Its prospects depend on regulatory progress, clinical trial results, physician adoption, reimbursement, and the company’s ability to fund and advance its development programs.